A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours

PHASE1,PHASE2

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped Fusion announced that it is discontinuing this study as part of a portfolio prioritization and assessment; Fusion no longer plans to pursue development of FPI-1966.

Conditions

Advanced Solid Tumor
Head and Neck Squamous Cell Carcinoma
Bladder Carcinoma
Susceptible FGFR3 Genetic Alterations
FGFR3
FGFR3 Overexpression
FGFR3 Receptor
FGFR3 Protein Overexpression
Ovarian Cancer
Colorectal Cancer
Breast Cancer
Liver Cancer
Lung Cancer
Gastric Cancer

Interventions

DRUG: [225Ac]-FPI-1966
DRUG: [111In]-FPI-1967
BIOLOGICAL: vofatamab

Sponsor

Fusion Pharmaceuticals Inc.